STAT

Opinion: Administrative delays threaten the promise of the 21st Century Cures Act

Congress did its part getting the 21st Century Cures Act signed into law. The Trump administration needs to write regulations to make it a reality.
President Barack Obama applauds after signing the 21st Century Cures Act into law in December 2016.

When President Barack Obama signed the landmark 21st Century Cures Act into law in December 2016, he was surrounded by elated Republican and Democratic lawmakers. At the time, Obama said the measure would bring “to reality the possibility of new breakthroughs to some of the greatest health challenges of our time.”

Republican Sen. Lamar Alexander, who chairs the Senate’s Committee on Health, Education Labor, and Pensions, hailed the act as “a Christmas miracle … that will help virtually every American family.”

Their statements weren’t hyperbole. The bipartisan medical innovation package was chock-full of policies to modernize the National Institutes of Health and the Food and Drug Administration, combat the nationwide opioid epidemic, advance Obama’s Precision Medicine Initiative, and speed approval of new, lifesaving therapies for the most devastating of diseases.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks